Annals of Hepatology (Feb 2024)

Hepatic injury biomarkers in COVID-19

  • Diana K. Tapia-Calderón,
  • Ana I. Tornel-Avelar,
  • Francisco A. Félix-Téllez,
  • Lydia A. Mercado-Jáuregui,
  • Liliana E. Ramos-Villalobos,
  • Bladimir Diaz-Villavicencio,
  • Monserrat Lazcano-Becerra,
  • Rodrigo Escobedo-Sánchez,
  • Edgar S. García-Jiménez,
  • José A. Velarde-Ruiz Velasco

Journal volume & issue
Vol. 29
p. 101459

Abstract

Read online

Introduction and Objectives: : C-reactive protein (CRP) and D-dimer have been shown to be predictors of severity in patients with COVID-19. The FIB-4 and APRI scoring systems are tools calculated using routine laboratory parameters that allow non-invasive evaluation of liver fibrosis. Some studies have demonstrated that the parameters comprising these scores predict mortality in COVID-19. The objective of this study was to determine the role of various liver injury biomarkers in stratifying the severity of hospitalized patients with COVID-19. Materials and Patients: Analytical and retrospective study. Patients with COVID-19 were included, while those with liver disease were excluded. A receiver operating characteristic (ROC) analysis with 95% confidence intervals (CI) was performed to determine the predictive performance of FIB-4, APRI, D-dimer, and CRP in terms of the need for invasive mechanical ventilation (IMV) and mortality. Results: A total of 448 hospitalized patients with COVID-19 were included in the study. 68.2% were male, with a mean age of 56.27 ± 14.7 years. 35.1% had systemic arterial hypertension, 29.2% had diabetes mellitus, 6% had cancer, 5% had chronic obstructive pulmonary disease, and 3.3% had chronic kidney disease. 21.4% required nasal cannula support, 29.4% required mask with reservoir, 35.5% required high-flow oxygen therapy, and 13.1% required IMV. 48% had severe disease, and 28.1% died. ROC analysis with 95% CI revealed that the best predictor of the need for IMV was the FIB-4 index, with an AUC of 0.637 (95% CI 0.545 - 0.732, p= 0.003), followed by APRI with an AUC of 0.596 (95% CI 0.504-0.687, p=0.04). The best predictor of mortality was FIB-4 with an AUC of 0.689 (95% CI 0.620 - 0.785, p= <0.001), followed by D-dimer with an AUC of 0.608 (95% CI 0.528 - 0.688, p= 0.041). Conclusions: The application of the FIB-4 index with a cutoff point of ≥1.9 predicts IMV and mortality in SARS-CoV-2 infection and is superior to the standard severity biomarkers (CRP and D-dimer).